Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Celestica Inc (CLS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Celestica IncTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Celestica Inc vs Inovio Pharmaceuticals Inc — how do they compare? Celestica Inc trades at $336.56 (market cap $39.16B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Celestica Inc is far larger — about 498.5× Inovio Pharmaceuticals Inc's market cap, and Celestica Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CLSINO
Market Cap
$39.16B$78.55M
Sector
TechnologyHealth
52-Week High
$472.40$2.87
52-Week Low
$181.34$0.66
Enterprise Value
$39.44B$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Celestica Inc

CLS trades at $336.97, up 7.11% on the day, with a bearish technical signal from moving averages but strong fundamental performance. The company reported three consecutive quarterly EPS beats, with Q2 2026 actual EPS of $2.54 exceeding the $2.29 estimate. Revenue for 2025 was $12.39 billion, with a net income margin of 7.16% and robust ROE of 52.69%. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, alongside new contracts with key tech partners.

The outlook is supported by accelerating AI-driven demand and raised guidance, but near-term dilution from the equity raise poses a risk. Analyst consensus is strongly bullish with a $466.50 price target, though the stock's premium valuation requires careful monitoring of execution against growth expectations.

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

Returns comparison

Trailing returns across standard periods

About Celestica Inc

Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.

Read more on CLS

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO